Depot Medroxyprogesterone Acetate for Sickle Cell Pain
This study is looking at whether an injectable birth control called Depot Medroxyprogesterone Acetate (DMPA), also known as Depo-Provera, can help reduce pain for women with sickle cell disease (SCD). We are enrolling women aged 18 to 50 who have SCD and experience at least one painful episode (vaso-occlusive episode) per month. Participants will first have a 3-month period without hormonal birth control, followed by a 3-month period after receiving a 150mg injection of DMPA. The main goal is to see if the frequency of painful episodes changes after 6 months. This study aims to enroll 65 participants.
- Study design
- This is an interventional study involving adult women with sickle cell disease. It includes a baseline period followed by a period after receiving the intervention.
- What's involved
- You would have 6 to 7 in-person visits for urine pregnancy tests, blood draws, and surveys. You would also complete weekly remote surveys and monthly home pregnancy tests over a 6-month period.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, frequency of acute vaso-occlusive episodes, is measured at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Andrea Roe, MD MPH · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Frequency of acute vaso-occlusive episodes6 months
The primary outcome is frequency of VOEs during each phase (baseline and intervention). A VOE is self-reported by the participant. Discrete pain episodes will be separated by at least 2 weeks from one other. During both the baseline and intervention study phases, participants will provide weekly reports via electronic survey of vaso-occlusive pain. VOE will be defined as self-reported typical SCD pain that interferes with usual daily activities or requires emergency care or hospitalization, with distinct episodes separated by at least 2 weeks without pain.